Temozolomide-associated organizing pneumonitis

Fabien Maldonado, Andrew H. Limper, Kaiser G. Lim, Marie Christine Aubry

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Temozolomide is an oral alkylating agent recently approved for the treatment of glioblastoma multiforme. It has a favorable side effect profile and is generally well tolerated. Although mild respiratory symptoms have been described, pulmonary toxicity that requires discontinuation of therapy is rare. To our knowledge, this is the first case of temozolomide-associated organizing pneumonitis.

Original languageEnglish (US)
Pages (from-to)771-773
Number of pages3
JournalMayo Clinic proceedings
Volume82
Issue number6
DOIs
StatePublished - Jun 2007

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Temozolomide-associated organizing pneumonitis'. Together they form a unique fingerprint.

Cite this